Periodontal Therapeutics Market Size was valued at USD 0.3 billion in 2022 and is projected to grow from USD 0.3 Billion in 2023 to USD 0.73 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.3% during the forecast period (2023 - 2032). Due to the rise in oral health problems worldwide, periodontal therapy is expanding quickly. The development of novel therapeutic products with the assistance of numerous organizations accelerates the market growth. These are major market drivers for the expansion of market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
A chronic inflammatory condition known as the periodontal disease affects the bone-supporting teeth and the gums. Left untreated may lead to tooth loss and other serious health problems. Early treatment of periodontal disease is necessary to prevent chronic inflammation, which raises the risk of diabetes, insulin resistance, and decreased glucose tolerance. The earlier it is addressed, the better. Almost 90% of people worldwide are afflicted with periodontal diseases, making them the most prevalent dental condition. Globally, the prevalence of oral disorders is rising due to expanding urbanization and modifications in livable conditions. Periodontitis affects an estimated 3.5 billion individuals worldwide, according to the World Health Organization (WHO). Furthermore, more than 1 billion adults worldwide, or around 19% of the adult population, are thought to be affected by severe periodontal diseases.
The Centers for Disease Control and Prevention estimate that 42.2% of persons 30 and older have periodontal disease. The condition in the United States afflicts more males than women. As a result, the prevalence of periodontal illnesses raises the need for treatment, which fuels the growth of the periodontal treatment industry.
The Periodontal Therapeutics Market segmentation, based on type, includes chronic Periodontitis, aggressive Periodontitis, and necrotizing periodontal. The chronic periodontitis segment held the majority share in 2022, contributing to around ~65-67% of the Periodontal Therapeutics Market revenue. This is primarily owing to the rising prevalence of periodontitis disease and the growing aging population across the globe. The prevalence of tooth gum disease is typically proportional to age, as the age of the population increases, the prevalence of Periodontitis or oral healthcare issues increases.
Whereas the aggressive periodontitis segment is expected to grow at the fastest growth rate. The aggressive periodontitis market is expanding significantly due to aggressive Periodontitis being more prevalent in a diverse population of younger people who may or may not be otherwise healthy.
The FDA approved the cavity-spotting AI from VideaHealth. The AI was developed and trained using the vast collection of dental X-rays from VideaHealth's Videa Factory, which the company touts as the most diverse data set in the dental industry. Insurers, clearinghouses, institutions, and dental service providers have contributed over 100 million data points. According to reports, AI has enabled dentists to miss 43% fewer caries lesions. They made 15% fewer incorrect diagnoses as a result.
The Periodontal Therapeutics Market segmentation based on treatment includes systematic antibiotics and others. The systematic antibiotics segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Surgical procedures are recommended less often than systemic antibiotic therapies, such as periodontal scaling, root planing, and antibiotics for periodontal disease treatment. Systematic antibiotics are in high demand since they are less invasive than surgery, less painful, and take less time to complete.
The treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are refractory to radioactive iodine (RAI) or who are ineligible for RAI and who have progressed during or after prior systemic therapy has recently received approval from the European Commission for CABOMETYX (cabozantinib) as a monotherapy. With this permission, CABOMETYX may be marketed for this use in all 27 members of the European Union, as well as in Norway, Liechtenstein, and Iceland.
End users have bifurcated the Periodontal Therapeutics Market data into dental hospitals and others. The dental hospital segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. For the majority of dental-related problems, people prefer to consult a dentist. As a result, dental clinic procedures have grown.
Due to the quick adoption of cutting-edge periodontal therapy goods and the accessibility of qualified dental, and medical professionals, dental hospitals held the greatest segment share. The expansion of the periodontal therapeutic market is also anticipated to be supported by rising government initiatives to enhance the oral healthcare infrastructure and the rising number of periodontal therapeutic procedures, including chronic periodontal surgery.
Figure 1: Periodontal Therapeutics Market by End User, 2022 & 2030 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Periodontal Therapeutic Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America periodontal therapeutics market accounted for USD 0.14 billion in 2022 and is expected to exhibit a significant market share of 45.8% in 2022. This is attributed to a rise in scientific study and cutting-edge technology that may broaden the potential for periodontal therapy advancement. Over 47.2% of Americans aged 30 and over have periodontal disease, according to the Centers for Disease Control and Prevention. Age-related increases in prevalence are seen; 70.1% of persons 65 and older have periodontal disease. The need for periodontal therapy in the area has increased as a result.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: PERIODONTAL THERAPEUTICS MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Due to the availability of state-of-the-art treatment facilities, government support for expanding the dental healthcare sector, an aging population, and an increase in chronic and aggressive periodontitis illness, Europe periodontal therapeutics market holds the second-largest share. Also, the UK periodontal therapeutic market grew the fastest in the European Region, while Germany periodontal therapeutic market had the significant market share.
A higher CAGR is anticipated for the Asia Pacific periodontal therapeutics market throughout the projected period. The increase in oral disease prevalence is blamed for this. The burden of periodontal disease is greatest in Southeast Asia and the Western Pacific, whereas the prevalence is lowest, according to the Journal of Public Health & Emergency. The highest rise over the previous three years was likewise seen in the Western Pacific. The Region is also a very lucrative market due to the Region's increased knowledge, increased adoption of periodontal therapy, and increased assistance from governing authorities. Moreover, China periodontal therapeutics market held the largest market share, and the India periodontal therapeutics market was the fastest growing market in the Asia-Pacific region.
Periodontal Therapeutic Key Market Players & Competitive Insights
Major market players are investing heavily in R&D to expand their product lines, which will help the periodontal therapeutics market grow even further. Market participants are also pursuing a variety of strategic initiatives to expand their global footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. To expand and survive in an increasingly competitive and rising market environment, periodontal therapeutics industry must offer cost-effective items.
One of the primary business strategies adopted by manufacturers in the periodontal therapeutics industry to benefit clients and expand the market sector is to expand their production capacity and are adopt innovative technologies in order to meet consumer demand for periodontal therapeutics. The periodontal therapeutics market major player such as Fibrocell Sciences, Tolmar Inc, Eli Lilly & Company, and Align Technology. And others are working on expanding the market demand by investing in research and development activities.
Envista is an international group of more than 30 reputable dental companies with a common goal: to work with experts to enhance lives. Envista uses market-leading goods, solutions, and technology to assist its partners in providing the best patient care possible. An estimated 90% of dentists' clinical needs for diagnosing, treating, and preventing dental diseases are met by its complete portfolio, which includes dental implants and treatment alternatives, orthodontics, and digital imaging technology. Envista Holding Corporation and the Spanish dental services provider Vitaldent Group entered a strategic alliance in February 2022. This aids the business in being the go-to source for dental implants.
Also, The main provider of dental lasers and a pioneer in dental technology is AMD LASERS. For dentists ready to advance their practice, AMD has offered ultra-affordable laser technology for over ten years. To raise the bar for patient care, our mission is to guarantee that every dental practitioner and practice has access to cutting-edge medical and dental technologies and educational resources. The Monet laser cutting light, the first portable laser in curing light for dental materials, was introduced by AMD Lasers in February 2020.
Key Companies in the periodontal therapeutics market include
Periodontal Therapeutic Industry Developments
February 2022:Â The Vitaldent Group, a dental services provider with offices in Spain, and Envista Holdings Corporation have renewed their collaboration agreement to deliver implants and clear aligners.
March 2021:Â Positive topline phase 2 results from the randomized placebo-controlled clinical trial evaluating AMY101 in 39 patients with Periodontitis and gingivitis were released by Amyndas Pharmaceuticals.
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.3 billion |
| Market Size 2023 | USD 0.33 billion |
| Market Size 2032 | USD 0.73 billion |
| Compound Annual Growth Rate (CAGR) | 10.3% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Fibrocell Sciences, Tolmar Inc, Eli Lilly & Company, Align Technology, Dentsply International, 3M-ESPE,  Ultradent Products Inc, Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals Int. |
| Key Market Opportunities | High Demand for Non-surgical Periodontal Treatment |
| Key Market Dynamics | Increase in the Number of Periodontitis Patients Sedentary Lifestyle, Unhealthy Diet, and Smoking |
Frequently Asked Questions (FAQ) :
The Periodontal Therapeutics Market size was valued at USD 0.3 Billion in 2022.
The global market is projected to grow at a CAGR of 10.3% during the forecast period 2023-2032.
North America had the largest share of the global market.
The key players in the market are Fibrocell Sciences, Tolmar Inc, Eli Lilly & Company, and Align Technology.
The chronic periodontitis category dominated the market in 2022.
The systematic antibiotics segment had the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
